Safety and efficacy of investigator-prescribed BeneFIX® prophylaxis in children less than 6 years of age with severe haemophilia B

Haemophilia

Volumn 16, Issue 3, 2010, Pages 460-468

  Monahan, P E ^a   Liesner, R ^b   Sullivan, S T ^c   Ramirez, M E ^c   Kelly, P ^c   Roth, D A ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

BeneFIX; Factor IX; Haemophilia; Prophylaxis; RFIX

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CORTICOSTEROID; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CATHETER INFECTION; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COUGHING; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; HEMARTHROSIS; HEMATOMA; HEMOPHILIA B; HUMAN; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOSIS; TREATMENT DURATION; URTICARIA;

CHILD; CHILD, PRESCHOOL; FACTOR IX; FEMALE; HEMARTHROSIS; HEMOPHILIA B; HEMORRHAGE; HUMANS; INFANT; MALE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS;

EID: 77953578591     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02162.x     Document Type: Article

References (29)

1. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003, 9:1-23.
2. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Intern Med 1997, 241:395-400.
3. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992, 232:25-32.
4. Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996, 92:973-8.
5. Shapiro AD, Donfield SM, Lynn HS. Defining the impact of hemophilia: the academic achievement in children with hemophilia study. Pediatrics 2001, 108:105-10.
6. Fischer K, van der Bom J, Mauser-Bunschoten E. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002, 99:2337-41.
7. Tagariello G, Iorio A, Santagostino E. Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood 2009, 114:779-84.
8. Roberts H, Eberst M. Current management of hemophilia B. Hematol Oncol Clin North Am 1993, 7:1269-80.
9. Harrison S, Adamson S, Bonam D. The manufacturing process for recombinant factor IX. Semin Hematol 1998, 35:4-10.
10. Kaufman RJ, Wasley LC, Furie BC, Furie B, Shoemaker CB. Expression, purification, and characterization of recombinant γ-carboxylated factor IX synthesized in Chinese hamster ovary cells. J Biol Chem 1986, 261:9622-8.
11. World Federation of Hemophilia Report on the Annual Global Survey 2006 2007, Montreal, Quebec, Canada, World Federation of Hemophilia
12. Kreuz W, Escuriola-Ettinghausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start? The German experience. Haemophilia 1998, 4:413-7.
13. Shapiro A, Di Paola J, Cohen A. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 2005, 105:518-25.
14. Manco-Johnson M, Abshire T, Shapiro A. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007, 357:535-44.
15. Tagliaferri A, Franchini M, Coppola A. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008, 14:945-51.
16. Bjorkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia 2001, 7:133-9.
17. Poon M-C. Pharmacokinetics of factors IX, recombinant human activated factor VII and factor XIII. Haemophilia 2006, 12:61-9.
18. Lambert T, Recht M, Valentino L. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia 2007, 13:233-43.
19. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001, 98:3600-6.
20. Sultan Y. The French Hemophilia Study Group. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost 1992, 67:600-2.
21. Thorland E, Drost J, Lusher J. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 1999, 5:101-5.
22. Katz J. Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey. Haemophilia 1996, 2:28-31.
23. Lusher J. Inhibitors in young boys with haemophilia. Best Pract Res Clin Haematol 2000, 13:457-68.
24. Warrier I. Antibodies to factor IX. Haematologica 2000, 85:31-4.
25. Warrier I. Inhibitors in Hemophilia B. Textbook of Hemophilia 2005, 97-100. Lee CBerntorp EHoots W. In, eds, Oxford, UK and Malden, MA, Blackwell Publishing
26. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006, 12:15-22.
27. Green P, Bentley D, Mibashan R, Nilsson I, Giannelli F. Molecular pathology of haemophilia B. EMBO J 1989, 8:1067-72.
28. Ljung R, Petrini P, Tengborn L, Sjorin E. Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity. Br J Haematol 2001, 113:81-6.
29. Valentino L, Ewenstein B, Navickis R, Wilkes M. Central venous access devices in haemophilia. Haemophilia 2004, 10:134-46.